Werewolf Therapeutics' stock continues to be monitored by investors as the company advances its clinical programs and strives to redefine the role of cytokines in treating serious diseases.

Werewolf Therapeutics' stock continues to be monitored by investors as the company advances its clinical programs and strives to redefine the role of cytokines in treating serious diseases. The ...

Werewolf Therapeutics, Inc. (NASDAQ:HOWL), a biotechnology company with a market capitalization of $76.2 million focused on developing novel therapeutics for oncology and inflammatory diseases, has ...

Clinical trial setbacks could significantly impact Werewolf Therapeutics' stock performance. The company's valuation is heavily dependent on the success of its pipeline candidates, particularly ...